Locations:
Search IconSearch
November 26, 2025/Cancer/News & Insight

Artificial Intelligence in Oncology (Podcast)

Real-world applications in clinical documentation and trial matching

There are a number of different ways that artificial intelligence (AI) may be coming into play in the field of oncology.

In a recent episode of the Cancer Advances podcast, Jame Abraham, MD, FACP, Chair of the Department of Hematology & Medical Oncology at the Cleveland Clinic Cancer Institute, joins podcast host Dale Shepard, MD, PhD, to share how AI can impact clinicians' work.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Podcast excerpt:

Dale Shepard, MD, PhD: Can you highlight the things we're doing clinical trial basis. So, one of the hard parts about clinical trials is you see a patient in front of you and you say, "Well, I've got all these trials. What might my patient qualify for?" Maybe highlight a little bit about how we're trying to do trial matching activities.

Jame Abraham, MD: As all of us clearly understand, clinical trial is the gold standard of cancer treatment. And here, in the adults in the US, less than 10% of patients go on clinical trial. And that's due to many reasons. One reason is, as you said, it's so complex to understand the criteria, who meets the criteria, who doesn't meet the criteria.

So, the AI-based technology, Cleveland Clinic is partnering with a company to help us to identify patients who can potentially be eligible for certain trials. And they'll help the clinicians to cut through the noise and select the patients for the trial.

Dale Shepard, MD, PhD: And I guess the good part about that is some of these products, if someone might not have qualified because their white blood cell count was too low, it will go back and then tell you, if those numbers change, whether they're now eligible.

Jame Abraham, MD: Right. Which is huge.

Advertisement

Related Articles

Researcher with microscope
June 26, 2026/Cancer

Testosterone May Offer Anti-Tumor Activity in Glioblastoma

Research findings offer clues for improving disease outcomes in men

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Ad